skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine

Abstract

A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days post-vaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL® at the same dose used in the first study, followed by FMDV A24/Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration ofmore » AdtA24 formulated in ENABL® adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.« less

Authors:
; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1617388
Alternate Identifier(s):
OSTI ID: 1580736
Grant/Contract Number:  
AC05-06OR23100; HSHQPD-07-X-00003; HSHQDC-14-F-00035; GS-23F-80006H; HSHQDC-8-C-00011
Resource Type:
Journal Article: Published Article
Journal Name:
Vaccine
Additional Journal Information:
Journal Name: Vaccine Journal Volume: 36 Journal Issue: 8; Journal ID: ISSN 0264-410X
Publisher:
Elsevier
Country of Publication:
United Kingdom
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; Foot-and-mouth disease virus; FMDV A24/Cruzeiro/BRA/55; Recombinant human adenovirus vectored vaccine; DIVA; Vaccine efficacy; Adjuvant

Citation Formats

Barrera, José, Schutta, Christopher, Pisano, Melia, Grubman, Marvin J., Brake, David A., Miller, Timothy, Kamicker, Barbara J., Olutunmbi, Femi, Ettyreddy, Damodar, Brough, Douglas E., Butman, Bryan T., and Neilan, John G. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine. United Kingdom: N. p., 2018. Web. doi:10.1016/j.vaccine.2018.01.026.
Barrera, José, Schutta, Christopher, Pisano, Melia, Grubman, Marvin J., Brake, David A., Miller, Timothy, Kamicker, Barbara J., Olutunmbi, Femi, Ettyreddy, Damodar, Brough, Douglas E., Butman, Bryan T., & Neilan, John G. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine. United Kingdom. doi:10.1016/j.vaccine.2018.01.026.
Barrera, José, Schutta, Christopher, Pisano, Melia, Grubman, Marvin J., Brake, David A., Miller, Timothy, Kamicker, Barbara J., Olutunmbi, Femi, Ettyreddy, Damodar, Brough, Douglas E., Butman, Bryan T., and Neilan, John G. Thu . "Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine". United Kingdom. doi:10.1016/j.vaccine.2018.01.026.
@article{osti_1617388,
title = {Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine},
author = {Barrera, José and Schutta, Christopher and Pisano, Melia and Grubman, Marvin J. and Brake, David A. and Miller, Timothy and Kamicker, Barbara J. and Olutunmbi, Femi and Ettyreddy, Damodar and Brough, Douglas E. and Butman, Bryan T. and Neilan, John G.},
abstractNote = {A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days post-vaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL® at the same dose used in the first study, followed by FMDV A24/Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration of AdtA24 formulated in ENABL® adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.},
doi = {10.1016/j.vaccine.2018.01.026},
journal = {Vaccine},
issn = {0264-410X},
number = 8,
volume = 36,
place = {United Kingdom},
year = {2018},
month = {2}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at 10.1016/j.vaccine.2018.01.026

Citation Metrics:
Cited by: 9 works
Citation information provided by
Web of Science

Save / Share: